COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Nation's health outcomes gain recognition
- Sichuan's ethnic festival attracts thousands of tourists
- SCO Digital Economy University Alliance launched
- Experience from a first-person perspective a sniper shooting from a boat
- Humble root crop becomes vital industry in Haikou village
- Sniper showdown on water: Realistic battlefield simulation
